These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21692415)

  • 1. Celiac disease manifested during the treatment of chronic hepatitis C by pegylated alpha interferon and ribavirin.
    Gombosova L; Jarcuska P; Benova B; Benicky M; Lazurova I
    Bratisl Lek Listy; 2011; 112(6):360-2. PubMed ID: 21692415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Celiac disease onset after pegylated interferon and ribavirin treatment of chronic hepatitis C.
    Martins EV; Gaburri AK
    Arq Gastroenterol; 2004; 41(2):132-3. PubMed ID: 15543388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C].
    Abellán Galiana P; Pérez-Lázaro A; Aguilera Sancho-Tello V; Merino Torres JF; Berenguer Haym M; Piñón Sellés F
    Endocrinol Nutr; 2009 Mar; 56(3):136-9. PubMed ID: 19627727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New-onset psoriasis following treatment with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C.
    Horev A; Halevy S
    Isr Med Assoc J; 2009 Dec; 11(12):760-1. PubMed ID: 20166347
    [No Abstract]   [Full Text] [Related]  

  • 5. Tuberculosis complicating treatment of hepatitis C in an HIV-infected haemophilia A patient.
    Killingley B; Bhagani S; Slapak G; Yee TT; Johnson M
    Haemophilia; 2006 Sep; 12(5):545-7. PubMed ID: 16919087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C].
    Burgueño-Montañés C; Pérez-Álvarez R
    Arch Soc Esp Oftalmol; 2011 Jun; 86(6):193-5. PubMed ID: 21767697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should routine screening for celiac disease be considered before starting interferon/ribavirin treatment in patients affected by chronic hepatitis C or not?
    Nejad MR; Alavian SM
    Bratisl Lek Listy; 2012; 113(4):251. PubMed ID: 22502761
    [No Abstract]   [Full Text] [Related]  

  • 8. Taste disturbances during therapy with pegylated interferon-alpha 2b and ribavirin in patients with chronic hepatitis C.
    Klimacka-Nawrot E; Musialik J; Suchecka W; Petelenz M; Hartman M; Lichtański P; Błońska-Fajfrowska B
    Wiad Lek; 2010; 63(4):289-99. PubMed ID: 21608370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B; Kovács B; Battyáni Z
    Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Thyroid dysfunctions in children with chronic hepatitis C during interferon alpha-2b therapy].
    Kupś-Rzepecka J; Woźniakowska-Gesicka T; Gołabek V
    Przegl Lek; 2011; 68(6):311-5. PubMed ID: 22039668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
    Halász T; Farkas A; Tolvaj G; Horváth G
    Orv Hetil; 2006 Feb; 147(7):321-4. PubMed ID: 17489160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
    Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
    Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
    J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Side effects of interferon-based therapy for chronic hepatitis C virus infection and clinical management of them].
    Iwasaki Y; Ikeda F; Yamamoto K
    Nihon Rinsho; 2011 May; 69 Suppl 4():215-20. PubMed ID: 22096922
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pegylated intereferon hematological safety in comparison with standard].
    Fazylov VKh; Manapova ÉR; Tkacheva SV; Sozinova IuM
    Eksp Klin Gastroenterol; 2012; (6):96-9. PubMed ID: 23402198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
    J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV.
    Slim J; Afridi MS
    Infect Dis Clin North Am; 2012 Dec; 26(4):917-29. PubMed ID: 23083824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin.
    Fouad YM; Khalaf H; Ibraheem H; Rady H; Helmy AK
    Int J Infect Dis; 2012 Jan; 16(1):e67-71. PubMed ID: 22115957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon and ribavirin treatment for chronic hepatitis C may activate celiac disease.
    Adinolfi LE; Durante Mangoni E; Andreana A
    Am J Gastroenterol; 2001 Feb; 96(2):607-8. PubMed ID: 11232725
    [No Abstract]   [Full Text] [Related]  

  • 20. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
    Mousa N; Besheer T; Gad Y; Elbendary A; Mokbel T; Abdel-Aziz A
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):345-8. PubMed ID: 23113644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.